AbbVie Reports Strong Q3 2026 Earnings, Raises Full-Year Guidance & Hikes Dividend 5.2%

AbbVie Inc. Q3 2026 Earnings & Operating Highlights

AbbVie Inc. filed Form 8-K under Item 2.02 detailing its third-quarter 2026 financial performance, guidance update, and dividend declaration.

Key Financial Results

• Net Revenues: Worldwide net revenues reached $17.404 billion, representing a 10.3% year-over-year increase on a reported basis (10.5% operational).
• Diluted EPS: Reported GAAP diluted EPS of $2.37; adjusted diluted EPS came in at $3.82 (both up >100% year-over-year, including a $0.11 per share unfavorable impact from acquired IPR&D and milestones).
• Margins: GAAP gross margin ratio of 75.4% (adjusted: 85.1%); operating margin was 36.0% (adjusted: 48.7%).

Portfolio Performance

• Immunology ($9.165B, +16.3%): Driven by strong growth in Skyrizi ($5.776B, +22.7%) and Rinvoq ($2.706B, +23.9%), offsetting Humira erosion ($683M, -31.2%).
• Neuroscience ($3.389B, +19.4%): Strong contributions from Botox Therapeutic ($1.080B, +9.8%), Vraylar ($1.068B, +14.3%), Ubrelvy ($449M, +26.9%), and Qulipta ($398M, +38.2%).
• Oncology ($1.696B, +0.8%): Venclexta revenue was $803M (+10.7%) and Elahere rose to $224M (+31.0%), offsetting lower Imbruvica revenue ($522M, -26.1%).
• Aesthetics ($1.176B, -1.4%): Botox Cosmetic revenue rose to $669M (+4.9%), while Juvederm totaled $222M (-11.9%).

Full-Year 2026 Guidance & Capital Return

• Guidance Raise: AbbVie raised its full-year 2026 adjusted diluted EPS guidance range to $13.95 - $13.99 (previously $13.76 - $13.96), incorporating $0.69 per share in YTD acquired IPR&D and milestones expenses.
• Dividend Increase: The board declared a 5.2% quarterly dividend boost from $1.73 to $1.82 per share, payable February 16, 2027 to shareholders of record as of January 15, 2027.

Strategic & Pipeline Updates

• Completed the acquisition of Apogee Therapeutics, adding assets including zumilokibart (IL-13) and APG273 (IL-13/TSLP).
• Achieved FDA approval for Skyrizi subcutaneous induction for Crohn's disease and Juvmo (tavapadon) tablets for Parkinson's disease.